NASDAQ · Financial Statements
Celyad Oncology S.A. (CYAD) Financial Statements
$0.47
NASDAQ: CYAD
Market Cap $14.24M
Overview Financials Dividend Celyad Oncology S.A. most recently reported annual revenue of $0, net profit of $-6.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024 Revenue $0 $0 $0 $0 $0 Operating Profit $-17.0M $-26.0M $-41.0M $-8.0M $-6.0M Net Profit $-18.0M $-27.0M $-41.0M $-8.0M $-6.0M EPS $-1.26 $-1.70 $-1.81 $-0.33 $-0.14 Op Margin -339740.0% — — -8291.2% -3149.5%
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024 Total Assets $66.0M $80.0M $20.0M $16.0M — Total Liabilities $35.0M $36.0M $15.0M $10.0M — Cash $17.0M $30.0M $12.0M $7.0M — Borrowings $4.0M $3.0M $0 $1.0M $0
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024 Operating Cash Flow $-28.0M $-27.0M $-28.0M $-15.0M — Investing Cash Flow $0 $-1.0M $7.0M $0 — Financing Cash Flow $7.0M $41.0M $4.0M $10.0M — Net Cash Flow $-22.0M $13.0M $-18.0M $-5.0M — Free Cash Flow $-28.0M $-27.0M $-28.0M $-16.0M $0
Valuation & Return Ratios
Metric Value PEG Ratio -0.03 EV / EBITDA -1.15 FCF Yield -128.85% Quick Ratio 3.79 Interest Coverage 0.00 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock